Materials and methods: Patients with resectable NSCLC with epidermal growth factor receptor (EGFR) mutation who received osimertinib as neoadjuvant therapy followed by surgery at our center were included. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.